Onyx Pharmaceuticals, Inc. v. Bayer Corporation et al

Filing 61

STIPULATION AND ORDER amended pretrial and trial schedules; Signed by Judge Marilyn Hall Patel on 11/16/2010. (awb, COURT STAFF) (Filed on 11/17/2010)

Onyx Pharmaceuticals, Inc. v. Bayer Corporation et al

Doc. 61

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

LAWRENCE R. KATZIN (CA SBN 142885) [e-mail] AMY C. DACHTLER (CA SBN 248589) [e-mail] MORRISON & FOERSTER LLP 425 Market Street San Francisco, California 94105-2482 Telephone: [phone] Facsimile: [phone] MARK L. LEVINE (admitted pro hac vice) [e-mail] JASON L. PELTZ (admitted pro hac vice) [e-mail] BRIAN C. SWANSON (admitted pro hac vice) [e-mail] J. SCOTT MCBRIDE (admitted pro hac vice) [e-mail] BARTLIT BECK HERMAN PALENCHAR & SCOTT LLP 54 West Hubbard St., Suite 300 Chicago, IL 60654-5697 Telephone: [phone] Facsimile: [phone] Attorneys for Defendants BAYER CORPORATION; BAYER HEALTHCARE LLC; BAYER AG; BAYER SCHERING PHARMA AG UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF CALIFORNIA SAN FRANCISCO DIVISION ONYX PHARMACEUTICALS, INC., Plaintiff, v. BAYER CORPORATION, et al., Defendants. Case No. CV 09 2145 MHP STIPULATION AND [PROPOSED] ORDER REVISING TRIAL DATE AND PRETRIAL SCHEDULE

AS AMENDED BY COURT

IT IS HEREBY STIPULATED by and between plaintiff Onyx Pharmaceuticals, Inc. ("Onyx") and defendants Bayer Corporation, Bayer AG, Bayer HealthCare LLC and Bayer Schering Pharma AG (collectively, "Bayer") as follows:
STIPULATION AND [PROPOSED] ORDER REVISING TRIAL DATE AND PRETRIAL SCHEDULE CASE NO. CV 09 2145 MHP

sf-2919431

Dockets.Justia.com

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

1.

WHEREAS, on August 21, 2009, the parties submitted the initial joint case

management statement proposing trial in May 2011, and on August 31, 2009, as a result of the initial case management conference, this Court entered an Order setting this matter for trial on May 17, 2011; 2. WHEREAS, on August 2, 2010, the Court entered a supplemental case

management Order that shifted some dates but maintained the May 17, 2010 trial date; 3. WHEREAS, the parties have been extremely busy producing millions of pages of

documents and completing 20 depositions all over the world. But given the remaining discovery, the parties respectfully request an approximate four-week extension of remaining due dates as set forth below. The parties also proposed additional language to provide clarity regarding what needs to be accomplished on each date; 4. WHEREAS, Onyx believes the trial date need not be continued, but is willing to

compromise and agree to this approximate four-week extension. Onyx only agrees to this new schedule, however, if the Court can accommodate a trial beginning on June 13, 2011. Otherwise, Onyx believes the Court should adopt the stipulated deadlines below for fact discovery and expert discovery (events 1, 2, 3 and 6) and should maintain all other deadlines according to the current schedule; 5. WHEREAS, given the remaining work, Bayer believes the schedule should be

shifted at least 90 days but is willing to compromise and agree to this approximate four-week extension. Bayer remains hopeful that, if both parties use their best efforts, the remaining discovery can be accomplished and the parties can heed these proposed new dates. But given the tightness of the proposed schedule, should circumstances necessitate, Bayer reserves the right to request a further extension of the schedule if necessary and upon a showing of good cause. Bayer believes that Onyx's alternative proposal (should the Court not be able to accommodate a trial beginning on June 13, 2011) to shift some of the deadlines but not others is unworkable and creates conflicts and prejudice; and 6. WHEREAS, the remaining discovery outstanding includes: Ten fact depositions, two of which require international travel;
STIPULATION AND [PROPOSED] ORDER REVISING TRIAL DATE AND PRETRIAL SCHEDULE CASE NO. CV 09 2145 MHP

2

sf-2919431

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

Twenty hours of deposition for individuals listed on the parties' witness lists who have not yet been deposed; Bayer's responses to Onyx's twenty new requests for production, which were timely served on October 19, 2010; Bayer's responses to Onyx's seventeen new interrogatories (Bayer believes there are more than seventeen given subparts), which were timely served on October 19, 2010; Bayer's responses to Onyx's eighteen new requests for admission, which were timely served on October 19, 2010; Production of documents by Onyx in response to Bayer's ten new requests for production, which were timely served on October 12, 2010; and Production of documents by both parties from certain new custodians, THEREFORE, the parties stipulate and jointly move the Court to enter a revised case management Order reflecting the following revised schedule:

STIPULATION AND [PROPOSED] ORDER REVISING TRIAL DATE AND PRETRIAL SCHEDULE CASE NO. CV 09 2145 MHP

3

sf-2919431

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 9. Deadline to hear motions on merits 18 10. Joint Pretrial Conf Statement and Order 19 11. Exhibit and Testimony Objections 20 12. Pretrial Conference 21 13. Trial 22 23 24 25 26 27 28
STIPULATION AND [PROPOSED] ORDER REVISING TRIAL DATE AND PRETRIAL SCHEDULE CASE NO. CV 09 2145 MHP

Event 1. Fact discovery deadline

Current Schedule 11/18/10

Revised Schedule 12/17/10 (but no new written discovery) 1/10/11

2. Exchange of expert reports by the party bearing the burden of proof on the issues raised in the expert report 3. Exchange of responding party expert reports 4. Trial witness disclosures, listing witnesses the parties in good faith intend to call at trial 5. Supplemental trial witness disclosures (only for "good cause" based on initial trial witness disclosures and responding party's expert reports) 6. Expert discovery deadline 7. Depose trial witnesses not yet deposed (20 hour total limit) 8. Deadline to file motions on merits

12/2/10

1/7/11 1/11/11

2/7/11 1/14/11

None

2/11/11

2/4/11 2/16/11 2/7/11 3/14/11 4/6/11 4/20/11 4/27/11 5/17/2011

3/04/11 3/04/11 3/14/11 4/18/11 5/06/11 5/20/11 5/31/11 6/1/11 at 2:30 pm 6/13/11 6/14/11 at 8:30 am

4

sf-2919431

1 2

IT IS SO STIPULATED. Dated: November 16, 2010 LAWRENCE R. KATZIN AMY C. DACHTLER MORRISON & FOERSTER LLP MARK L. LEVINE JASON L. PELTZ BRIAN C. SWANSON J. SCOTT MCBRIDE BARTLIT BECK HERMAN PALENCHAR & SCOTT LLP By: /s/ Lawrence R. Katzin LAWRENCE R. KATZIN Attorneys for Defendants BAYER CORPORATION, BAYER AG, BAYER HEALTHCARE LLC, and BAYER SCHERING PHARMA AG Dated: November 16, 2010 STEPHEN C. NEAL MARTIN S. SCHENKER MICHELLE S. RHYU BRADLEY A. WAUGH COOLEY LLP By: /s/ Michelle S. Rhyu MICHELLE S. RHYU Attorneys for Plaintiff ONYX PHARMACEUTICALS, INC.

3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

STIPULATION AND [PROPOSED] ORDER REVISING TRIAL DATE AND PRETRIAL SCHEDULE CASE NO. CV 09 2145 MHP

5

sf-2919431

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

SUPPLEMENTAL CASE MANAGEMENT ORDER This Stipulation and [Proposed] Order Revising Trial Date and Pretrial Schedule is hereby adopted by the Court as the Case Management Order for the case. IT IS SO ORDERED

11/16/2010 Dated: ________________________

ER

N

D IS T IC T R

OF

STIPULATION AND [PROPOSED] ORDER REVISING TRIAL DATE AND PRETRIAL SCHEDULE CASE NO. CV 09 2145 MHP

A

C

LI

FO
6

arilyn Judge M

l H. Pate

sf-2919431

R NIA

_________________________________ DERED The Honorable Marilyn H. Patel SO OR IT IS United States District Court Judge

UNIT ED

S

S DISTRICT TE C TA

RT U O

NO

RT

H

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

GENERAL ORDER 45 ATTESTATION In accordance with General Order 45, concurrence in the filing of this document has been obtained from each of the signatories and I shall maintain records to support this concurrence for subsequent production for the court if so ordered or for inspection upon request by a party.

/s/ Lawrence R. Katzin LAWRENCE R. KATZIN Attorneys for Defendants BAYER CORPORATION, BAYER AG, BAYER HEALTHCARE LLC, and BAYER SCHERING PHARMA AG

STIPULATION AND [PROPOSED] ORDER REVISING TRIAL DATE AND PRETRIAL SCHEDULE CASE NO. CV 09 2145 MHP

7

sf-2919431